Update
$Centessa Pharmaceuticals (CNTA.US)$ Press Release: Centessa Pharmaceuticals Announces $100 Million Proposed Public Offering of American Depositary Shares
Dow Jones· 15 mins ago
Centessa Pharmaceuticals Announces $100 Million Proposed Public Offering of American Depositary Shares
BOSTON and LONDON, April 23, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today announced that it has commenced an underwritten public offering of $100 million of American Depositary Shares ("ADSs"), each representing one ordinary share. All of the ADSs are being offered by Centessa. In addition, Centessa intends to grant the underwriters a 30-day option to purchase up to an additional $15 million of ADSs offered in the public offering. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Goldman Sachs and Leerink Partners are acting as lead joint book-running managers for the proposed offering. Evercore ISI, Guggenheim Securities and BMO Capital Markets are also acting as joint book-running managers for the proposed offering.
Dow Jones· 15 mins ago
Centessa Pharmaceuticals Announces $100 Million Proposed Public Offering of American Depositary Shares
BOSTON and LONDON, April 23, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today announced that it has commenced an underwritten public offering of $100 million of American Depositary Shares ("ADSs"), each representing one ordinary share. All of the ADSs are being offered by Centessa. In addition, Centessa intends to grant the underwriters a 30-day option to purchase up to an additional $15 million of ADSs offered in the public offering. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Goldman Sachs and Leerink Partners are acting as lead joint book-running managers for the proposed offering. Evercore ISI, Guggenheim Securities and BMO Capital Markets are also acting as joint book-running managers for the proposed offering.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Jaguar8 : A big ouch
Trytosaveabit OP Jaguar8 : Not as bad as I thought!
Jaguar8 Trytosaveabit OP : CYN was bad haha
Trytosaveabit OP Jaguar8 : Yes it was! Hehehe
Jaguar8 Trytosaveabit OP : I’m sure a lot got caught off guard and end up bagholding. Scaling out is key
Trytosaveabit OP Jaguar8 : Yup yup! Im in total agreement with that complete statement! Hehehe
Jaguar8 Trytosaveabit OP : Sometimes hoping for the moon and the sun will make you end up crashing back to earth![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined")
Jaguar8 Jaguar8 : Someone was even mad at me since he was hoping the stock will go back to 26 and price of stock is like 2-3. I told him unlikely unless there is mega deal that will skyrocket it. And I told him, don’t chase highs- he got mad haha. Reality bites.
Trytosaveabit OP Jaguar8 : True dat!
Trytosaveabit OP Jaguar8 : Yes a lot really get butthurt if you try to give facts that they don’t want to believe! Hehehe